FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2134946779> ?p ?o ?g. }

• W2134946779 endingPage "1072" @default.
• W2134946779 startingPage "1064" @default.
• W2134946779 abstract "Objective. Intravenously administered infliximab, a monoclonal antibody directed against tumor necrosis factor-α, has been proven to be efficacious in the treatment of fistulas in patients with Crohn's disease. It has recently been suggested that local injections of infliximab might be beneficial as well. The aim of this study was to assess whether infliximab could play an effective role in the local treatment of perianal fistulas in Crohn's disease. Material and methods. Local infliximab injections were administered to 11 patients suffering from Crohn's disease complicated by perianal disease. Eligible subjects included Crohn's disease patients with single or multiple draining fistulas, regardless of status of luminal disease at baseline. Patients, however, were excluded from the study if they had perianal or rectal complications, such as abscesses or proctitis or if they had previously been treated with infliximab. Twenty-milligram doses of infliximab were injected along the fistula tract and around both orifices at baseline and then every 4 weeks for up to 16 weeks or until complete cessation of drainage. No further doses were administered to patients who did not respond after three injections. Efficacy was measured in terms of response (a reduction in fistula drainage of 50% or more) and remission (complete cessation of fistula drainage for at least 4 weeks). Time to loss of response and health-related quality of life were also evaluated. Results. Overall, 8/11 patients (72.7%) responded to the therapy and 4/11 (36.4%) reached remission, whereas 3/11 patients (27.2%) showed no response. Response or remission was very much dependent on the location of the fistulas, and time to loss of response was generally longer for patients who reached remission compared to patients in response. Changes in health-related quality of life, as assessed by the Inflammatory Bowel Disease Questionnaire (IBDQ), also reflected response or remission, with more marked improvements associated with remission. After a mean 10.5 months’ follow-up (range 7–18 months), 6/11 patients (54.5%) are in response and 4/11 patients (36.4%) are in remission. No adverse events have been observed in this cohort of patients. Conclusions. Local injections of infliximab along the fistula tract seem to be an effective and safe treatment of perianal fistulas in Crohn's disease. However, further controlled clinical investigations are warranted." @default.
• W2134946779 created "2016-06-24" @default.
• W2134946779 creator A5013598906 @default.
• W2134946779 creator A5017852900 @default.
• W2134946779 creator A5025743103 @default.
• W2134946779 creator A5033621477 @default.
• W2134946779 creator A5047209658 @default.
• W2134946779 date "2006-01-01" @default.
• W2134946779 modified "2023-10-06" @default.
• W2134946779 title "Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-α accounts for a favourable clinical response in selected cases: A pilot study" @default.
• W2134946779 cites W1606079165 @default.
• W2134946779 cites W1607808246 @default.
• W2134946779 cites W1706367474 @default.
• W2134946779 cites W1970387245 @default.
• W2134946779 cites W1976546496 @default.
• W2134946779 cites W1977669101 @default.
• W2134946779 cites W1979173163 @default.
• W2134946779 cites W1998101952 @default.
• W2134946779 cites W2011111248 @default.
• W2134946779 cites W2011507560 @default.
• W2134946779 cites W2016587777 @default.
• W2134946779 cites W2021343859 @default.
• W2134946779 cites W2023254757 @default.
• W2134946779 cites W2024293518 @default.
• W2134946779 cites W2026116536 @default.
• W2134946779 cites W2027334329 @default.
• W2134946779 cites W2034855435 @default.
• W2134946779 cites W2038535814 @default.
• W2134946779 cites W2044095516 @default.
• W2134946779 cites W2052496052 @default.
• W2134946779 cites W2060864012 @default.
• W2134946779 cites W2061297752 @default.
• W2134946779 cites W2061736459 @default.
• W2134946779 cites W2066513063 @default.
• W2134946779 cites W2068436510 @default.
• W2134946779 cites W2070906416 @default.
• W2134946779 cites W2075396988 @default.
• W2134946779 cites W2090685459 @default.
• W2134946779 cites W2091385020 @default.
• W2134946779 cites W2102531478 @default.
• W2134946779 cites W2112340015 @default.
• W2134946779 cites W2127693350 @default.
• W2134946779 cites W2131999276 @default.
• W2134946779 cites W2154026057 @default.
• W2134946779 cites W2170555303 @default.
• W2134946779 cites W2171341132 @default.
• W2134946779 cites W2314055620 @default.
• W2134946779 cites W2321453230 @default.
• W2134946779 cites W2326330820 @default.
• W2134946779 cites W2417412366 @default.
• W2134946779 cites W4231456852 @default.
• W2134946779 cites W4236521244 @default.
• W2134946779 cites W4251237509 @default.
• W2134946779 cites W4293258177 @default.
• W2134946779 cites W4300931992 @default.
• W2134946779 cites W4376595675 @default.
• W2134946779 doi "https://doi.org/10.1080/00365520600609941" @default.
• W2134946779 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16938720" @default.
• W2134946779 hasPublicationYear "2006" @default.
• W2134946779 type Work @default.
• W2134946779 sameAs 2134946779 @default.
• W2134946779 citedByCount "81" @default.
• W2134946779 countsByYear W21349467792012 @default.
• W2134946779 countsByYear W21349467792013 @default.
• W2134946779 countsByYear W21349467792014 @default.
• W2134946779 countsByYear W21349467792015 @default.
• W2134946779 countsByYear W21349467792016 @default.
• W2134946779 countsByYear W21349467792017 @default.
• W2134946779 countsByYear W21349467792018 @default.
• W2134946779 countsByYear W21349467792019 @default.
• W2134946779 countsByYear W21349467792020 @default.
• W2134946779 countsByYear W21349467792021 @default.
• W2134946779 countsByYear W21349467792022 @default.
• W2134946779 countsByYear W21349467792023 @default.
• W2134946779 crossrefType "journal-article" @default.
• W2134946779 hasAuthorship W2134946779A5013598906 @default.
• W2134946779 hasAuthorship W2134946779A5017852900 @default.
• W2134946779 hasAuthorship W2134946779A5025743103 @default.
• W2134946779 hasAuthorship W2134946779A5033621477 @default.
• W2134946779 hasAuthorship W2134946779A5047209658 @default.
• W2134946779 hasConcept C126322002 @default.
• W2134946779 hasConcept C141071460 @default.
• W2134946779 hasConcept C2776341189 @default.
• W2134946779 hasConcept C2777138892 @default.
• W2134946779 hasConcept C2779134260 @default.
• W2134946779 hasConcept C2779280984 @default.
• W2134946779 hasConcept C2779686005 @default.
• W2134946779 hasConcept C2779810446 @default.
• W2134946779 hasConcept C2780120127 @default.
• W2134946779 hasConcept C2780132546 @default.
• W2134946779 hasConcept C2780479503 @default.
• W2134946779 hasConcept C523026621 @default.
• W2134946779 hasConcept C71924100 @default.
• W2134946779 hasConcept C90924648 @default.
• W2134946779 hasConceptScore W2134946779C126322002 @default.
• W2134946779 hasConceptScore W2134946779C141071460 @default.
• W2134946779 hasConceptScore W2134946779C2776341189 @default.
• W2134946779 hasConceptScore W2134946779C2777138892 @default.

• next